Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib for myeloprotection in first-line chemotherapy for advanced solid tumors (multi-cohort, open-label)
ChiCTR2400082382Phase 4Recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trilaciclib in Nonhematologic neoplasms, sponsored by The First Hospital of Jilin University. Primary endpoints: Incidence of severe neutropenia (SN) and Incidence of febrile neutropenia (FN). Started Mar 2024; status: recruiting.
02
Drugs
trilaciclib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2400082382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082382.